A summary of data presented at the XIV conference on new antiepileptic drug and devices (EILAT XIV)

Meir Bialer; Svein I Johannessen; Matthias J Koepp; René H Levy; Emilio Perucca; Torbjörn Tomson; H Steve White

doi:10.1016/j.eplepsyres.2019.03.002

A summary of data presented at the XIV conference on new antiepileptic drug and devices (EILAT XIV)

Epilepsy Res. 2019 Jul:153:66-67. doi: 10.1016/j.eplepsyres.2019.03.002. Epub 2019 Mar 11.

Authors

Meir Bialer¹, Svein I Johannessen², Matthias J Koepp³, René H Levy⁴, Emilio Perucca⁵, Torbjörn Tomson⁶, H Steve White⁷

Affiliations

¹ Institute for Drug Research, School of Pharmacy and David R. Bloom Centre for Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel. Electronic address: meirb@ekmd.huji.ac.il.
² The National Center for Epilepsy, Sandvika, Oslo University Hospital, Oslo, Norway; Department of Pharmacology, Oslo University Hospital, Oslo, Norway.
³ Department of Clinical and Experimental Epilepsy, UCL Institute of Neurology, London, UK.
⁴ Department of Pharmaceutics, University of Washington, Seattle, WA, USA; Department of Neurological Surgery, University of Washington, Seattle, WA, USA.
⁵ Division of Clinical and Experimental Pharmacology, Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy; IRCCS Mondino Foundation, Pavia, Italy.
⁶ Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden.
⁷ Department of Pharmacy, School of Pharmacy, University of Washington, Seattle, WA, USA.

PMID: 30910314
DOI: 10.1016/j.eplepsyres.2019.03.002

Abstract

The Fourteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIV) took place in Madrid, Spain from May 13th to 16th 2018. Again, presentations on new medical devices and neuromodulation and discussions on device-related regulatory aspects were included in the programme. The virtual special issue on "neuromodulation" summarises the presentations focusing firstly, on the pre-clinical developments and the difficulties of clinical trial designs for neuromodulatory therapies, including vagus nerve stimulation (VNS) and Brain-Responsive Neurostimulation (RNS), and the use of transcutaneous vagus nerve stimulation (tVNS) as a potential screening tool for determining the efficacy of neuromodulatory treatments in individual patients; secondly, on wearable devices for seizure monitoring through indices of peripheral sympathetic nervous activity, the use of such devices in combination with biofeedback for the treatment of epilepsy, and its potential for improving epilepsy specialist services, particularly in remote areas.

Publication types

Editorial
Introductory Journal Article

MeSH terms

Animals
Anticonvulsants / therapeutic use*
Clinical Trials as Topic
Congresses as Topic
Epilepsy / therapy*
Humans
Spain
Vagus Nerve Stimulation / instrumentation
Vagus Nerve Stimulation / methods*
Wearable Electronic Devices*

Substances

Anticonvulsants